A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 99-107

  Ware, Mark A ^a,d   Daeninck, Paul ^b   Maida, Vincent ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b CancerCare Manitoba   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Chemotherapy induced nausea vomiting; Nabilone; Pain

Indexed keywords

ALIZAPRIDE; ANTINEOPLASTIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; CANNABINOID; CANNABIS; CHLORPROMAZINE; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; DOMPERIDONE; DRONABINOL; HALOPERIDOL; LEVONANTRADOL; METOCLOPRAMIDE; NABILONE; ONDANSETRON; PLACEBO; PROCHLORPERAZINE; SEROTONIN ANTAGONIST;

ANTICIPATORY NAUSEA AND VOMITING; ANTIEMETIC ACTIVITY; ATAXIA; CANCER PAIN; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC PAIN; CLINICAL TRIAL; COORDINATION; DISORIENTATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUPHORIA; EVENING DOSAGE; FOOD INTAKE; HUMAN; INCREASED APPETITE; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHIC PAIN; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; TESTIS CANCER; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 41549095862     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Aapro M, Molassiotis A, Oliver I. 2005. Anticipatory nausea and vomiting. Support Care Cancer, 13:117-21.
2. Abrahm JL. 2005. A physician's guide to pain and symptom management in cancer patients. 2nd ed. Baltimore, MD: The Johns Hopkins University Press.
3. Ahmedzai S, Carlyle DL, Calder IT, et al. 1983. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer, 48:657-63.
4. Andrews PLR, Naylor RJ, Joss RA. 1998. Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies. Support Care Cancer, 6:197-203.
5. Aprepitant (Emend®). 2005. [package insert]. Merck and Co., Inc.
6. Ben Amar M. 2006. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol, 105:1-25.
7. Berlach DM, Shir Y, Ware MA. 2006. Experience with the synthetic cannabinoid in chronic noncancer pain. Pain Med, 7:25-29.
8. Bonica JJ. 1990. Evolution and current status of pain programs. J Pain Symptom Manage, 5:368-74.
9. Chan HS, Correia JA, MacLeod SM. 1987. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics, 79:946-52.
10. Crawford SM, Buckman R. 1986. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother, 3:39-42.
11. Croxford JL. 2003. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs, 17:179-202.
12. Cunningham, D, Bradley, CJ, Forrest, GJ, et al. 1988. A randomized trial of oral nabilone and prochlorperazine, compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol, 24:685-9.
13. Daut RL, Cleeland CS. 1982. The prevalence and severity of pain in cancer. Cancer, 50:1913-18.
14. Diana MA, Mart A. 2004. Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol, 142:9-19.
15. Einhorn LH, Nagy C, Furnas B, Williams SD. 1981. Nabilone: An effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol, 21(suppl):64-69.
16. Fabre LF, McLendon D. 1981. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol, 21:377S.
17. Freund TF, Katona I, Piomelli D. 2003. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev, 83:1017-66.
18. Fride E, Bregman T, Kirkham TC. 2005. Endocannabinoids and food intake: Newborn suckling and appetite regulation in adulthood. Exp Bio Med, 230:225-34.
19. Gralla RJ, de Wit R, Hertstedt J, et al. 2005. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer, 104:864-8.
20. Grunberg SM. 1989. Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. Blood Rev, 3:216-21.
21. Herman TS, Einhorn LH, Jones SE, et al. 1979. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med, 300:1295-7.
22. Herman TS, Jones SE, Dean J, et al. 1977. Nabilone: a potent antiemetic cannabinol with minimal euphoria. Biomedicine, 27:331-4.
23. Hickok JT, Roscoe JA, Morrow GR, et al. 2003. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer, 97:2880-6.
24. Hornby PJ. 2001. Central neurocircuitry associated with emesis. Am J Med, 111 (suppl 8A): 106-12.
25. Howlett AC, Barth F, Bonner TI, et al. 2002. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev, 54:161-202.
26. Jenns K. 1994. Importance of nausea. Cancer Nurs, 17:488-93.
27. Kalant H. 2001. Medicinal use of cannabis: history and current status. Pain Res Manage, 6:80-91.
28. Kris MG, Hesketh PJ, Somerfield MR, et al. 2006. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol, 24:2932-47.
29. Lee J, Dibble SL, Pickett M, et al. 2005. Chemotherapy-induced nausea/ vomiting and functional status in women treated for breast cancer. Cancer Nurs, 28:249-55.
30. Lemberger L, Rowe H. 1975. Clinical pharmacology of nabilone, a cannabinol derivative. Clin Pharm Ther, 18:720-26.
31. Limebeer CL, Hall G, Parker LA. 2006. Exposure to a lithium-paired context elicits gapin in rats: A model of anticipatory nausea. Physiol Behav, 88:398-403.
32. Lynch ME. 2005. Preclinical science regarding cannabinoids as analgesics: an overview. Pain Res Manage, 10(suppl A):7A-14A.
33. Mack A, Joy J. 2001. Marijuana as Medicine. Washington, DC: National Academy Press.
34. Malik IA, Khan WA, Qazilbash M et al. 1995. Clinical efficacy of lorazepam in prophylaxis of anticipatory acute and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol, 18:170-5.
35. Martin BR, Wiley JL. 2004. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol, 2:305-14; discussion 314-16.
36. Meiri, E, Jhangiani, H, Vredenburgh, JJ, et al. 2007. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin, 23:533-43.
37. Morran C, Smith DC, Anderson DA, et al. 1979. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. BMJ, 1:1323-4.
38. 3 antiemetics. Support Care Cancer, 6:244-7.
39. Nahas G, Harvey PJ, Sutin K, et al. 2002. A molecular basis of the therapeutic and psychoactive properties of cannabis (D9-tetrahydrocannabinol). Prog Neuro-Psychopharmacol Biol Psychiatry, 26:721-30.
40. National Cancer Institute. 2006. [online] Accessed 9 September 2006. URL: http://www.meds.com/pdq/supportive_pro.html.
41. National Comprehensive Cancer Network. 2006. Clinical Practice Guidelines in Oncology. Antiemesis. v2.2006 [online]. Accessed 9 September 2006. URL: http://www.neen.org.
42. Navari R. 2003. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting - two new agents. J Support Oncol, 1:89-103.
43. Niederle N, Schutte J, Schmidt CG. 1986. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonsemmomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr, 64:362-5.
44. Niiranen A, Mattson K. 1985. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol, 8:336-40.
45. Niiranen A, Mattson K. 1987. Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. Am J Clin Oncol, 10: 325-9.
46. Notcutt W, Price M, Miller R, et al. 2004. Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'N of I' studies. Anaesthesia, 59:440-52.
47. Parker LA, Kemp SW. 2001.Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: an animal model of anticipatory nausea and vomiting (ANV). Neuroreport, 12:749-51.
48. Parker LA, Kwiatkowska M, Mechoulam R. 2006. Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting. Physiol Behav, 87:66-71.
49. Piomelli D. 2003. The molecular logic of endocannabinoid signaling. Nat Rev Neurosci, 4:873-84.
50. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. on behalf of the Aprepitant Protocol 054 Study Group. 2003. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer, 97:3090-8.
51. Pomeroy M, Fennelly JJ, Towers M. 1986. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol, 17:285-88.
52. Priestman TJ, Priestman SG. 1984. An initial evaluation of nabilone in the control of radiotherapy-induced nausea and vomiting. Clin Radiol, 35:265-6.
53. Priestman SG, Priestman TJ, Canney PA. 1987. A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea. Clin Radiol, 38:543-4.
54. Razavi D, Delvaux N, Farvacques C, et al. 1993. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol, 11:1384-90.
55. Roscoe JA, Morrow GR, Hickok JT, et al. 2000. Nausea and vomiting remain a significant clinical problem: J Pain Symptom Mange, 20:113-21.
56. Schlicker E, Kathmann M. 2001. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci, 22:565-72.
57. Schwartzberg L. 2006. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol, (suppl 1):3-8.
58. Shakespeare DT, Boggild M, Young C. 2003. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev, CD001332.
59. Stockhorst U, Klosterhalfen S, Klosterhalfen W, et al. 1993. Anticipatory nausea in cancer patients receiving chemotherapy: classical conditioning etiology and therapeutical implications. Integr Physiol Behav Sci, 28: 177-81.
60. Strasser F, Luftner D, Possinger K, et al. 2006. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol, 24:3394-400.
61. Sun CC, Bodurka DC, Weaver CB, et al. 2004. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer, 13:219-27.
62. Tramér MR, Carroll D, Campbell FA, et al. 2001. Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. BMJ, 323:1-8.
63. Vanscoy GJ, Fortner B, Smith R, et al. 2005. Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics. Commun Oncol, 2:127-132.
64. Vinciguerra V, Moore T, Brennan E. 1988. Inhalation marijuana as an antiemetic for cancer chemotherapy. N Y State J Med, 88:525-7.
65. Waknine Y. 2006. FDA approvals: Lumigan, Cesamet, Omnitrope. Medscape Medical News. July 14, 2006. Accessed 9 September 2006. URL: http://www.medscape.com/viewarticle/540937.
66. Ward A, Holmes B. 1985. Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs, 30:127-44.
67. Wiser W, Berger A. 2005. Practical management of chemotherapy-induced nausea and vomiting. Oncology, 19:637-45.
68. Wissel J, Haydn, Muller J, et al. 2006. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain. A double-blind placebo-controlled cross-over trial. J Neurol, 20:2218-20.